
SXTP Stock Forecast & Price Target
SXTP Analyst Ratings
Bulls say
60 Degrees Pharmaceuticals Inc demonstrated significant growth with revenues reaching $310,000, reflecting a 20% sequential increase and an impressive 145% year-over-year rise. This robust revenue performance suggests a positive trajectory in the firm's commercial activities, particularly in its quest to develop therapies targeting infectious diseases. Additionally, the anticipated reduction in R&D expenses coupled with a higher share count supports an upward revision of the FY25 earnings per share estimate, further indicating a favorable outlook for the company's financial health.
Bears say
60 Degrees Pharmaceuticals Inc is facing a negative outlook primarily due to a significant reduction in forecasted revenue, attributed to low visibility regarding the company's capacity to ramp up sales. The firm reported a decline in product revenues to $100,000, primarily due to supply constraints, although this was somewhat mitigated by Australian research grant revenues. Additionally, uncertainties surrounding regulatory approvals for new product indications and the potential for dilution from future financing present substantial risks to the company's financial stability.
This aggregate rating is based on analysts' research of 60 Degrees Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
SXTP Analyst Forecast & Price Prediction
Start investing in SXTP
Order type
Buy in
Order amount
Est. shares
0 shares